Orris
attachment
attachment

Interpret

analyse_media
Reading File
Searching the Web

ACR BI-RADS 4C definition malignancy probability tissue diagnosis biopsy

Searching PubMed

breast BI-RADS biopsy

Finding Sources
Finding Sources
Reading Web Page

https://cs.acr.org/-/media/ACR/Files/RADS/BI-RADS/US-Reporti…

The ultrasound report shows an abnormal, suspicious mass in the left breast:
  • Location: left breast, 4 to 6 o'clock position
  • Size: 20 × 29 mm (about 2 to 3 cm)
  • Appearance: irregular, hypoechoic (darker than surrounding tissue) lesion with minimal internal blood flow
  • BI-RADS 4C: this means high suspicion for cancer, but it is not a diagnosis. The estimated likelihood of malignancy is roughly more than 50% but less than 95%. A BI-RADS reference recommends tissue diagnosis, meaning biopsy, for this category.
  • Left armpit lymph nodes: a few are enlarged and have lost the normal fatty/echogenic hilum. This is suspicious, and the radiologist has written “? metastatic nodes.” It means spread to lymph nodes is possible, but this can only be confirmed by sampling the node.
Other breast tissues, nipple/areolar area, ducts, chest muscle, and calcifications were reported as normal.

What needs to happen next

Please arrange an urgent consultation with a breast surgeon or surgical oncologist, ideally within days. The usual next step is:
  1. Ultrasound-guided core-needle biopsy of the breast mass.
  2. Needle biopsy of a suspicious left axillary lymph node, often at the same visit.
  3. If cancer is confirmed, pathology tests including tumor type/grade and ER, PR, and HER2 receptor testing guide treatment. Further imaging may be planned by the specialist.
An ultrasound cannot prove cancer or confirm lymph-node spread. The biopsy result is the deciding test. Do not delay evaluation, but do not assume a final diagnosis before pathology.

Is it respectable directly or should chemo be admisnistered

Reading File
Finding Sources
Finding Sources
Searching PubMed

breast neoplasms AND neoadjuvant chemotherapy

Searching the Web

ASCO guideline neoadjuvant chemotherapy breast cancer biopsy hormone receptor HER2 operable

It may be operable/resectable, but this cannot be decided from ultrasound alone. A 2.9 cm breast mass with suspicious axillary nodes is often still treatable with curative intent, but the correct order is:
  1. Core-needle biopsy of the breast mass
  2. Needle biopsy of the suspicious axillary lymph node
  3. Pathology testing for ER, PR, HER2, tumor grade, and type
  4. Breast surgeon and medical oncologist decide the treatment sequence
Do not start chemotherapy before biopsy confirmation and receptor testing.

When surgery may come first

If the tumor is confirmed cancer but is clearly removable and its biology is suitable, treatment can be:
  • Surgery first, either breast-conserving surgery or mastectomy, with lymph-node assessment
  • Then treatment based on pathology: radiation, hormone tablets, chemotherapy, HER2-targeted treatment, or a combination.

When chemotherapy is given before surgery

Chemotherapy before surgery, called neoadjuvant chemotherapy, may be preferred if:
  • The lymph node is confirmed involved
  • The cancer is triple-negative or HER2-positive
  • The tumor needs shrinking to allow breast-conserving surgery
  • The surgeon believes surgery first would not remove the disease adequately
For an ER/PR-positive, HER2-negative cancer in a 69-year-old, some patients may instead receive surgery first or sometimes hormone treatment before surgery. The choice depends on the biopsy and overall fitness, including heart, kidney, liver function, diabetes, and daily functional status.
So the immediate priority is a breast surgeon/surgical oncologist appointment and ultrasound-guided biopsies of both the breast lump and left axillary node. The report alone does not mean chemotherapy must start immediately.
This is a shared conversation. Sign in to Orris to start your own chat.